Evidence map›Paper›PMID 23370446›Full record

ReviewCell cycle (Georgetown, Tex.)2013

New insights into prostate cancer stem cells.

Xin Chen, Kiera Rycaj, Xin Liu, Dean G Tang

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell cycle (Georgetown, Tex.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Advances in Prostate Cancer Biomarkers and Probes.Cyborg and bionic systems (Washington, D.C.) · 2024
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. A mNAR cancer · 2022
    Article
  12. Review
  13. Review
  14. Review
  15. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.American journal of clinical and experimental urology · 2021
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 4 countries.

Xin ChenDepartment of Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Smithville, TX, USA.
Kiera Rycaj
Xin Liu
Dean G Tang
The University of Texas MD Anderson Cancer Center · USTongji University · CN

Funding

Decoding NanogP8 in TumorigenesisR01CA155693 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI TANG, DEAN G. · 2012 to 2016
$1.6M
NCI NIH HHS R01 CA155693
6 · The paper itself

Abstract

Prostate cancer (PCa) remains one of the most prevalent malignancies affecting men in the western world. The etiology for PCa development and molecular mechanisms underlying castration-resistant progression are incompletely understood. Emerging evidence from many tumor systems has shown the existence of distinct subpopulations of stem like-cancer cells termed cancer stem cells (CSCs), which may be involved in tumor initiation, progression, metastasis and therapy resistance. Prostate cancer stem cells (PCSCs) have also been identified using different experimental strategies in distinct model systems. In this brief review, we summarize our current knowledge of normal prostate stem/progenitor cells, highlight recent progress on PCSCs, expound on the potential cell-of-origin for PCa and discuss the involvement of PCSCs in PCa progression and castration resistance. Elucidation of the phenotypic and functional properties and molecular regulation of PCSCs will help us better understand PCa biology and may lead to development of novel therapeutics targeting castration-resistant PCa cells.

Indexed as

Gene Expression Regulation, NeoplasticAndrogensAnimalsCell DifferentiationCell Transformation, NeoplasticDisease ProgressionHumansMaleMiceNeoplastic Stem CellsOrchiectomyProstateProstatic NeoplasmsReceptors, AndrogenSignal TransductionAndrogensReceptors, Androgencancer stem cellsdifferentiationprostate cancerprostate cancer stem cellstherapy resistance

Identifiers

PMID23370446
PMCPMC3594258
OpenAlexW1968021501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.